MedPath
HSA Approval

Lisdene Tablet 10mg

SIN13846P

Lisdene Tablet 10mg

Lisdene Tablet 10mg

August 6, 2010

NOVARTIS (SINGAPORE) PTE LTD

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09AA03

lisinopril

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

Salutas Pharma GmbH

Lek Pharmaceuticals d.d.

Lek Pharmaceuticals d.d. (Lendava) (Primary and Secondary Packager)

Active Ingredients

Lisinopril Dihydrate 10.89 mg eqv. Lisinopril

10 mg

Lisinopril

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Lisdene Tablet 10mg - HSA Approval | MedPath